Form 4: TuHURA CFO Dearborn Receives Significant Option Grant

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, was granted 273,696 stock options with an exercise price of $0.73, vesting over three years.

Summary

• Dan Dearborn, Chief Financial Officer of TuHURA Biosciences, Inc./NV (HURA), was granted 273,696 derivative securities in the form of stock options.
• The options have an exercise price of $0.73 per share.
• The transaction date for this grant was January 6, 2026.
• The options become exercisable in three equal annual installments, with one-third vesting on January 6, 2026, January 6, 2027, and January 6, 2028, respectively, based on the anniversary of January 6, 2025.
• The expiration date for these options is January 6, 2036.
• This grant represents a supplemental option grant to one previously made in December 2025.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, as it aligns management's interests with shareholders and incentivizes long-term performance. It reflects a standard compensation practice and commitment to executive retention.

Positives

• The option grant aligns the Chief Financial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over three years encourages retention of key management personnel.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged and transparent trading strategy.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, although this is standard for equity compensation.

Future Outlook

The option grant indicates a commitment to retaining and incentivizing key management, suggesting a focus on long-term value creation and stability within the executive team. The vesting schedule ties future compensation to continued service and potential stock price appreciation.

Industry Context

Executive compensation, particularly through equity grants like stock options, is a standard practice in the biotechnology and pharmaceutical industries. It serves to attract, retain, and motivate key talent, aligning their financial success with the company's performance and shareholder value. The use of Rule 10b5-1 plans is also common for executives to manage their equity holdings in a compliant manner.

Comparison to Industry Standards

• The granting of stock options to a Chief Financial Officer is a common form of executive compensation across the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity to incentivize leadership.
• The vesting schedule, typically over three to four years, is standard for such grants, ensuring long-term commitment from the executive.
• An exercise price set at or near the market price on the grant date is also a standard practice for incentive stock options, aligning the executive's potential gains directly with future stock price appreciation.

Corporate Governance

Related Party Transactions

• The grant of 273,696 stock options to Dan Dearborn, the Chief Financial Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from aligned management incentives for long-term stock price appreciation.
• Employees: May view this as a positive signal regarding executive retention and the company's commitment to its leadership.
• Management (Dan Dearborn): Receives significant equity incentive, tying personal wealth directly to the company's future performance.

Next Steps

• The stock options will vest in three annual installments, with the next vesting event occurring on January 6, 2027, and the final one on January 6, 2028.
• Dan Dearborn may choose to exercise these options at any point after they vest and before their expiration date of January 6, 2036, subject to company policy and market conditions.

Key Dates

Keywords

TuHURA Biosciences, HURA, Dan Dearborn, CFO, Stock Options, Equity Compensation, Insider Transaction, Form 4, Rule 10b5-1, Biotechnology